GSK plc 6-K, filed Mar 30, 2020
GSK plc (GSK)
6-K
2020-03-30
For: 2020-03-30
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on March 30, 2020.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
|
Issued: 30 March 2020, London, UK - LSE Announcement
GSK publishes Consumer Healthcare product sales
category reporting changes
|
|
GSK
keeps its financial reporting under regular review to ensure that
it remains current and in line with both the latest regulatory
requirements and developing best practice within the Pharmaceutical
industry.
Consumer Healthcare product sales categories updated
Following
the closing of the transaction that combined the assets of the
legacy GSK Consumer Healthcare business with Pfizer consumer
healthcare on 31 July 2019, GSK completed a review of the segment
sales disclosures applicable to the new Consumer Healthcare Joint
Venture business. A revised and more detailed disclosure of
category sales will provide greater transparency to the main
drivers of the Consumer Healthcare Joint Venture's
performance.
Previously
reported Nutrition and Skin health categories will no longer be
used as a result of GSK's focus in the portfolio on core categories
via targeted divestments. Nutrition, Skin health and the
category previously called "Wellness" will be replaced by four more
specific categories structured around GSK's global power
brand1 portfolio
and closely aligned to consumer healthcare industry standard
definitions:
● Oral health (unchanged) includes the power
brands Sensodyne, Parodontax and the Denture care franchise comprising
approximately 85%2 of
category sales. GSK leads the therapeutic Oral health segment
globally3.
● Pain relief includes the power
brands Voltaren, Panadol and Advil comprising 86%2 of
category sales with an additional 11% of sales from leading
regional brands ('local stars'). GSK holds the global #1 position
in this category4.
● Respiratory
health includes cold
& flu, allergy and cough brands. Combined power brands
(Theraflu and Otrivin) and 'local star' brands comprise over
70%2 of
category sales. GSK holds the global #1 position in this
category4.
● Vitamins, minerals and
supplements includes
power brand Centrum and 'local stars' Caltrate and Emergen-C as well as smaller brands that were
previously reported in the Nutrition category. Power brands and
'local stars' comprise over 70%2 of
category sales and GSK holds the global #1 position in this
category4.
●
Digestive health and
other includes 'local star' Digestive health
brands Tums, Nexium and Eno; the OTC Smokers' health franchise;
small dermatology brands previously reported in Skin health; and
any other products not reported elsewhere.
●
Brands divested and under
review includes those brands that have been divested
but remain in the comparative sales disclosures for 2019 and
earlier years; previously announced divestments including the sale
of the Horlicks and other family
nutrition brands in India and certain other markets to Hindustan
Unilever Ltd; and brands under review as part of the divestment
programme announced at the time of the formation of the joint
venture with Pfizer.
The
revised Consumer Healthcare turnover tables below set out the new
format for reporting Consumer Healthcare product sales that will be
used beginning with the Q1 2020 Results Announcement and applied to
the 2019 reported and pro forma Consumer Healthcare product
sales.
An
Excel version of this data is available on www.gsk.com.
_________________________________________________________________________________________________________________________________________________________________________________________________________________________________
_______________________________________________________________
1 GSK Consumer Healthcare
has a portfolio of nine global power brands and fifteen leading
regional ('local star') brands comprising over
70%2 of
total sales excluding brands divested and under
review.
2 Percentages are
estimated based on 2019 sales of legacy GSK and Pfizer consumer
healthcare brands.
3 GSK analysis based on Nielsen, IRI and
Euromonitor data.
4 Nicholas Hall's DB6 Consumer Healthcare database
2018.
|
|
|
|
GSK - one of the world's
leading research-based pharmaceutical and healthcare companies - is
committed to improving the quality of human life by enabling people
to do more, feel better and live longer. For further
information please visit www.gsk.com
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
Brand names
Brand names appearing in italics throughout this document are
trademarks of GSK or associated companies or used under licence by
the Group.
This Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The information for 2019 and 2018 has
been derived from the full Group accounts published in the Annual
Report 2019.
CER growth
In order to illustrate underlying performance, it is the Group's
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period.
Pro-forma growth
The acquisition of the Pfizer consumer healthcare business
completed on 31 July 2019 and so GSK's reported results for 2019
include five months of results of the former Pfizer consumer
healthcare business from 1 August 2019.
The Group has presented pro-forma growth rates at CER for turnover
taking account of this transaction. Pro-forma growth rates are
calculated for comparing reported results for the periods from 1
August 2019, calculated applying the exchange rates used in the
comparative period, with the results for periods from 1 August 2018
adjusted to include the equivalent results of the former Pfizer
consumer healthcare business during 2018, as consolidated (in US$)
and included in Pfizer's US GAAP results.
Cautionary statement regarding pro-forma growth rates
The pro-forma growth rates at CER in the press release have been
provided to illustrate the position in Q3 2019, nine months 2019,
Q4 2019 and year-ended 31 December 2019 relative to the position in
Q3 2018, nine months 2018, Q4 2018 and year-ended 31 December 2018
as if, for the purposes of the Q3 2018, nine months 2018, Q4 2018
and year-ended 31 December 2018, the acquisition of the Pfizer
consumer healthcare business had taken place as at 31 July 2018.
Accordingly, two months of results of the former Pfizer consumer
healthcare business were included in Q3 2018 and nine months 2018,
three months of results of the Pfizer consumer healthcare business
were included in Q4 2018 and five months of results of the former
Pfizer consumer healthcare business were included in the year-ended
31 December 2018. The results of the former Pfizer consumer
healthcare business included for Q3 2018, nine months 2018, Q4 2018
and year-ended 31 December 2018 are as consolidated (in US$) and
included in Pfizer's US GAAP results. The results for Q3 2019, nine
months 2019, Q4 2019 and the year-ended 31 December 2019 used to
calculate the pro-forma growth rates are as reported at
CER.
The pro forma growth rates have been provided for illustrative
purposes only and, by their nature, address a hypothetical
situation and therefore do not represent the Group's actual growth
rates. The pro-forma growth rates do not purport to represent what
the Group's results of operations would have actually been if the
Pfizer acquisition had been completed on the date indicated, nor do
they purport to represent the results of operations at any future
date. In addition, the pro-forma growth rates do not reflect the
effect of anticipated synergies and efficiencies or accounting and
reporting differences associated with the acquisition of the Pfizer
consumer healthcare business.
|
|
|
|
|
|
|
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
|
Revised format for reporting Consumer Healthcare product
sales The revised format for the reporting of Consumer
Healthcare product sales applied to the 2019 quarterly and 2018
full year Consumer Healthcare sales is as follows:
|
Consumer Healthcare turnover - year ended 31 December
2019
|
|
|
2019
|
||||||
|
|
|
|
|
|
|
Reported
|
|
Pro-forma
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
£%
|
CER%
|
|
CER%
|
||||
|
Oral health
|
|
2,673
|
|
7
|
|
7
|
|
7
|
|
Pain relief
|
|
1,781
|
|
24
|
|
24
|
|
4
|
|
Respiratory health
|
|
1,186
|
|
9
|
|
8
|
|
(2)
|
|
Vitamins, minerals and supplements
|
|
611
|
|
>100
|
|
>100
|
|
(3)
|
|
Digestive health and other
|
|
1,646
|
|
15
|
|
13
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,897
|
|
20
|
|
20
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
Brands divested and under review
|
|
1,098
|
|
-
|
|
(1)
|
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,995
|
|
17
|
|
17
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - three months ended 31 December
2019
|
|
|
Q4 2019
|
||||||
|
|
|
|
|
|
|
Reported
|
|
Pro-forma
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
£%
|
CER%
|
|
CER%
|
||||
|
Oral health
|
|
651
|
|
4
|
|
7
|
|
7
|
|
Pain relief
|
|
501
|
|
42
|
|
45
|
|
2
|
|
Respiratory health
|
|
354
|
|
21
|
|
22
|
|
(3)
|
|
Vitamins, minerals and supplements
|
|
332
|
|
>100
|
|
>100
|
|
(7)
|
|
Digestive health and other
|
|
473
|
|
35
|
|
38
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,311
|
|
41
|
|
43
|
|
1
|
|
Brands divested and under review
|
|
260
|
|
(3)
|
|
-
|
|
(10)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,571
|
|
35
|
|
37
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - nine months ended 30 September
2019
|
|
|
|
9 months 2019
|
||||||
|
|
|
|
|
|
|
Reported
|
|
Pro-forma
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
£%
|
CER%
|
|
CER%
|
||||
|
Oral health
|
|
2,022
|
|
8
|
|
6
|
|
6
|
|
Pain relief
|
|
1,280
|
|
18
|
|
17
|
|
5
|
|
Respiratory health
|
|
832
|
|
5
|
|
3
|
|
(2)
|
|
Vitamins, minerals and supplements
|
|
279
|
|
>100
|
|
>100
|
|
2
|
|
Digestive health and other
|
|
1,173
|
|
8
|
|
5
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,586
|
|
14
|
|
12
|
|
3
|
|
Brands divested and under review
|
|
838
|
|
1
|
|
(1)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,424
|
|
12
|
|
10
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - three months ended 30 September
2019
|
|
|
Q3 2019
|
||||||
|
|
|
|
|
|
|
Reported
|
|
Pro-forma
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
Growth
|
|
|
£%
|
CER%
|
|
CER%
|
||||
|
Oral health
|
|
709
|
|
14
|
|
10
|
|
10
|
|
Pain relief
|
|
526
|
|
43
|
|
40
|
|
6
|
|
Respiratory health
|
|
344
|
|
15
|
|
12
|
|
(1)
|
|
Vitamins, minerals and supplements
|
|
224
|
|
>100
|
|
>100
|
|
2
|
|
Digestive health and other
|
|
425
|
|
20
|
|
15
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,228
|
|
33
|
|
29
|
|
4
|
|
Brands divested and under review
|
|
298
|
|
8
|
|
3
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,526
|
|
30
|
|
25
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - six months ended 30 June
2019
|
|
|
|
6 months 2019
|
|
||||
|
|
|
|
|
|
|
Reported
|
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
|
|
£%
|
CER%
|
|
||||
|
Oral health
|
|
1,313
|
|
5
|
|
5
|
|
|
Pain relief
|
|
754
|
|
5
|
|
5
|
|
|
Respiratory health
|
|
488
|
|
(1)
|
|
(3)
|
|
|
Vitamins, minerals and supplements
|
|
55
|
|
2
|
|
4
|
|
|
Digestive health and other
|
|
748
|
|
2
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,358
|
|
3
|
|
3
|
|
|
Brands divested and under review
|
|
540
|
|
(2)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,898
|
|
2
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - three months ended 30 June
2019
|
|
|
Q2 2019
|
|
||||
|
|
|
|
|
|
|
Reported
|
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
|
|
£%
|
CER%
|
|
||||
|
Oral health
|
|
651
|
|
7
|
|
5
|
|
|
Pain relief
|
|
383
|
|
11
|
|
10
|
|
|
Respiratory health
|
|
197
|
|
4
|
|
2
|
|
|
Vitamins, minerals and supplements
|
|
29
|
|
7
|
|
11
|
|
|
Digestive health and other
|
|
398
|
|
4
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,658
|
|
7
|
|
5
|
|
|
Brands divested and under review
|
|
259
|
|
(5)
|
|
(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,917
|
|
5
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - three months ended 31 March
2019
|
|
|
|
3 months 2019
|
|
||||
|
|
|
|
|
|
|
Reported
|
|
|
|
|
£m
|
|
Growth
|
|
Growth
|
|
|
|
£%
|
CER%
|
|
||||
|
Oral health
|
|
662
|
|
4
|
|
4
|
|
|
Pain relief
|
|
371
|
|
(1)
|
|
-
|
|
|
Respiratory health
|
|
291
|
|
(5)
|
|
(5)
|
|
|
Vitamins, minerals and supplements
|
|
26
|
|
(4)
|
|
(4)
|
|
|
Digestive health and other
|
|
350
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,700
|
|
-
|
|
-
|
|
|
Brands divested and under review
|
|
281
|
|
-
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,981
|
|
-
|
|
1
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare turnover - twelve months ended 31 December
2018
|
|
|
|
|
|
|
|
2018
|
|
|
|
|
£m
|
|
|
|
|||
|
Oral health
|
|
2,496
|
|
|
Pain relief
|
|
1,440
|
|
|
Respiratory health
|
|
1,085
|
|
|
Vitamins, minerals and supplements
|
|
103
|
|
|
Digestive health and other
|
|
1,435
|
|
|
|
|
|
|
|
|
|
6,559
|
|
|
Brands divested and under review
|
|
1,099
|
|
|
|
|
|
|
|
|
|
7,658
|
|
|
|
|
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
30, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|